Compare · MRK vs ZTS
MRK vs ZTS
Side-by-side comparison of Merck & Company Inc. (MRK) and Zoetis Inc. (ZTS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRK and ZTS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $284.45B, about 8.7x ZTS ($32.52B).
- Over the past year, MRK is up 51.0% and ZTS is down 54.2% - MRK leads by 105.2 points.
- MRK has been more active in the news (15 items in the past 4 weeks vs 11 for ZTS).
- MRK has more recent analyst coverage (25 ratings vs 24 for ZTS).
- Company
- Merck & Company Inc.
- Zoetis Inc.
- Price
- $115.16-3.01%
- $77.60-0.05%
- Market cap
- $284.45B
- $32.52B
- 1M return
- +5.48%
- -32.50%
- 1Y return
- +50.98%
- -54.19%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- 2013
- News (4w)
- 15
- 11
- Recent ratings
- 25
- 24
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Zoetis Inc.
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. It also provides other pharmaceutical products, which comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives that offer medicines to livestock. In addition, the company offers portable blood and urine analysis systems, and point-of-care diagnostic products, including instruments and reagents, rapid immunoassay tests, reference laboratory kits, blood glucose monitors, and laboratory services; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision livestock farming. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
Latest MRK
- Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting
- SEC Form SD filed by Merck & Company Inc.
- FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)
- Merck & Company Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Merck Congratulates Ontario Government on Expanding Pharmacy Scope to Help Improve Access to Care
- Merck to Participate in the Jefferies Global Healthcare Conference
- Merck Announces Third-Quarter 2026 Dividend
- Merck & Company Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by Merck & Company Inc.
- Synergis Software Launches Adept Cloud, a Cloud-Native Engineering Document Management Platform Built for Asset-Intensive Industries
Latest ZTS
- SEC Form SD filed by Zoetis Inc.
- Zoetis downgraded by Argus
- Director Stetter Mark converted options into 1,572 shares (SEC Form 4)
- Zoetis Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders
- Director Parent Louise M converted options into 12,130 shares, increasing direct ownership by 75% to 28,394 units (SEC Form 4)
- Zoetis to Participate in Upcoming Investor Conferences
- Zoetis Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Zoetis Declares Third Quarter 2026 Dividend
- Director Damelio Frank A bought $501,344 worth of shares (6,650 units at $75.39), increasing direct ownership by 45% to 21,458 units (SEC Form 4)
- Director Bisaro Paul bought $151,750 worth of shares (2,000 units at $75.88), increasing direct ownership by 8% to 27,862 units (SEC Form 4)